Search results
Results from the WOW.Com Content Network
React (also known as React.js or ReactJS) is a free and open-source front-end JavaScript library [5] [6] that aims to make building user interfaces based on components more "seamless". [5] It is maintained by Meta (formerly Facebook) and a community of individual developers and companies.
Redux is an open-source JavaScript library for managing and centralizing application state. It is most commonly used with libraries such as React or Angular for building user interfaces. Similar to (and inspired by) Facebook's Flux architecture, it was created by Dan Abramov and Andrew Clark. Since mid-2016, the primary maintainers are Mark ...
Vite (French:, like "veet") is a local development server written by Evan You, [1] the creator of Vue.js, and used by default by Vue and for React project templates. It has support for TypeScript and JSX. It uses Rollup and esbuild internally for bundling. [2]
Version 5.0 of the Ext JS framework was released on June 2, 2014. [16] It includes the ability to build desktop apps on touch-enabled devices [ 17 ] —using a single code base, a Model View ViewModel ( MVVM ) architecture, two-way data binding, responsive layouts, and other component upgrades with support for adding widgets inside a grid cell ...
JSX (JavaScript XML, formally JavaScript Syntax eXtension) is an XML-like extension to the JavaScript language syntax. [1] Initially created by Facebook for use with React , JSX has been adopted by multiple web frameworks .
Today's NYT Connections puzzle for Saturday, December 14, 2024The New York Times
JSFiddle is an online IDE which is designed to allow users to edit and run HTML, JavaScript, and CSS code on a single page. [3] Its interface is minimalist and split into four main frames, which correspond to editable HTML, JavaScript and CSS fields and a result field which displays the user's project after it is run.
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the pharmaceutical giant offers investors a 4.3% dividend yield backed by a ...